PT  - JOURNAL ARTICLE
AU  - Carine Salliot
AU  - Claire Bombardier
AU  - Alain Saraux
AU  - Bernard Combe
AU  - Maxime Dougados
TI  - Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort
AID  - 10.1136/ard.2009.111179
DP  - 2010 Sep 01
TA  - Annals of the Rheumatic Diseases
PG  - 1683--1686
VI  - 69
IP  - 9
4099  - http://ard.bmj.com/content/69/9/1683.short
4100  - http://ard.bmj.com/content/69/9/1683.full
SO  - Ann Rheum Dis2010 Sep 01; 69
AB  - Objective To assess the effect of reproductive factors, especially hormone replacement therapy (HRT) and its interaction with HLA-DRB1 *01 and/or *04 alleles on the diagnosis of rheumatoid arthritis (RA) and the presence of anti-cyclic citrullinated peptide (CCP) antibodies in women included in the ESPOIR cohort (early arthritis cohort). Methods 568 patients were included in the analyses, which were performed using logistic regression. Results HRT reduced the risk of RA due to the HLA-DRB1 *01 and/or *04 alleles from OR 1.88 (95% CI 1.32 to 2.68, p<0.000) for HLA-DRB1 *01 and/or *04 alleles alone to OR 1.07 (95% CI 0.51 to 2.26, p=0.85) in women with HLA-DRB1 *01 and/or *04 alleles who received HRT. One explanation might be the protective effect of HRT on the presence of anti-CCP antibodies (OR 0.43, 95% CI 0.24 to 0.77, p<0.006). Other reproductive factors such as the number of pregnancies, menopause and age at menopause, age at menarche and a history of pregnancy with poor outcome were not associated with the diagnosis of RA and the presence of anti-CCP antibodies. Conclusion HRT may reduce the risk of RA due to HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP antibodies.